Literature DB >> 33302515

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer.

Laura C Zanetti-Domingues1, Scott E Bonner2, R Sumanth Iyer1, Marisa L Martin-Fernandez1, Veronica Huber3.   

Abstract

Epidermal growth factor receptor (EGFR) takes centre stage in carcinogenesis throughout its entire cellular trafficking odyssey. When loaded in extracellular vesicles (EVs), EGFR is one of the key proteins involved in the transfer of information between parental cancer and bystander cells in the tumour microenvironment. To hijack EVs, EGFR needs to play multiple signalling roles in the life cycle of EVs. The receptor is involved in the biogenesis of specific EV subpopulations, it signals as an active cargo, and it can influence the uptake of EVs by recipient cells. EGFR regulates its own inclusion in EVs through feedback loops during disease progression and in response to challenges such as hypoxia, epithelial-to-mesenchymal transition and drugs. Here, we highlight how the spatiotemporal rules that regulate EGFR intracellular function intersect with and influence different EV biogenesis pathways and discuss key regulatory features and interactions of this interplay. We also elaborate on outstanding questions relating to EGFR-driven EV biogenesis and available methods to explore them. This mechanistic understanding will be key to unravelling the functional consequences of direct anti-EGFR targeted and indirect EGFR-impacting cancer therapies on the secretion of pro-tumoural EVs and on their effects on drug resistance and microenvironment subversion.

Entities:  

Keywords:  EV biogenesis; EV heterogeneity; MVB heterogeneity; endocytosis; epidermal growth factor receptor (EGFR); extracellular vesicles (EVs); microenvironment subversion; therapy resistance; tumour microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33302515      PMCID: PMC7764760          DOI: 10.3390/cells9122639

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  235 in total

1.  EGFR signaling patterns are regulated by its different ligands.

Authors:  Stine Louise Jeppe Knudsen; Anni Sieu Wai Mac; Lasse Henriksen; Bo van Deurs; Lene Melsæther Grøvdal
Journal:  Growth Factors       Date:  2014-10       Impact factor: 2.511

Review 2.  EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.

Authors:  Eugene Tulchinsky; Oleg Demidov; Marina Kriajevska; Nickolai A Barlev; Evgeny Imyanitov
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-11-10       Impact factor: 10.680

Review 3.  Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.

Authors:  Daniel J Toft; Vincent L Cryns
Journal:  Mol Endocrinol       Date:  2010-09-22

4.  USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.

Authors:  Huijuan Zhang; Bing Han; Hailing Lu; Yanbin Zhao; Xuesong Chen; Qingwei Meng; Mengru Cao; Li Cai; Jing Hu
Journal:  Cancer Lett       Date:  2018-07-04       Impact factor: 8.679

Review 5.  Effects of endocytosis on receptor-mediated signaling.

Authors:  Roshanak Irannejad; Nikoleta G Tsvetanova; Braden T Lobingier; Mark von Zastrow
Journal:  Curr Opin Cell Biol       Date:  2015-06-06       Impact factor: 8.382

6.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.

Authors:  Michela Garofalo; Giulia Romano; Gianpiero Di Leva; Gerard Nuovo; Young-Jun Jeon; Apollinaire Ngankeu; Jin Sun; Francesca Lovat; Hansjuerg Alder; Gerolama Condorelli; Jeffrey A Engelman; Mayumi Ono; Jin Kyung Rho; Luciano Cascione; Stefano Volinia; Kenneth P Nephew; Carlo M Croce
Journal:  Nat Med       Date:  2011-12-11       Impact factor: 87.241

7.  Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family.

Authors:  Ying-Nai Wang; Mien-Chie Hung
Journal:  Cell Biosci       Date:  2012-04-20       Impact factor: 7.133

Review 8.  Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases.

Authors:  Federica Ciregia; Andrea Urbani; Giuseppe Palmisano
Journal:  Front Mol Neurosci       Date:  2017-08-31       Impact factor: 5.639

9.  The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers.

Authors:  Laura C Zanetti-Domingues; Dimitrios Korovesis; Sarah R Needham; Christopher J Tynan; Shiori Sagawa; Selene K Roberts; Antonija Kuzmanic; Elena Ortiz-Zapater; Purvi Jain; Rob C Roovers; Alireza Lajevardipour; Paul M P van Bergen En Henegouwen; George Santis; Andrew H A Clayton; David T Clarke; Francesco L Gervasio; Yibing Shan; David E Shaw; Daniel J Rolfe; Peter J Parker; Marisa L Martin-Fernandez
Journal:  Nat Commun       Date:  2018-10-18       Impact factor: 14.919

Review 10.  Extracellular Vesicles and Cancer: A Focus on Metabolism, Cytokines, and Immunity.

Authors:  Donatella Lucchetti; Claudio Ricciardi Tenore; Filomena Colella; Alessandro Sgambato
Journal:  Cancers (Basel)       Date:  2020-01-10       Impact factor: 6.639

View more
  3 in total

Review 1.  The dual functions of Rab11 and Rab35 GTPases-regulation of cell division and promotion of tumorigenicity.

Authors:  Paulius Gibieža; Vilma Petrikaitė
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 2.  Visualizing Extracellular Vesicles and Their Function in 3D Tumor Microenvironment Models.

Authors:  Evran E Ural; Victoria Toomajian; Ehsanul Hoque Apu; Mladen Veletic; Ilangko Balasingham; Nureddin Ashammakhi; Masamitsu Kanada; Christopher H Contag
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

Review 3.  Exosomes: a new perspective in EGFR-mutated lung cancer.

Authors:  Amina Jouida; Cormac McCarthy; Aurelie Fabre; Michael P Keane
Journal:  Cancer Metastasis Rev       Date:  2021-04-14       Impact factor: 9.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.